Life Biosciences doses first participant with ER-100, the first partial epigenetic reprogramming therapy given to a human

Life Biosciences/ER-100

Life Biosciences dosed the first participant in a Phase 1 trial of ER-100 for optic neuropathies including glaucoma and NAION. ER-100 uses controlled expression of OCT4, SOX2 and KLF4 to reset retinal ganglion cells to youthful epigenetic patterns.

• Partial epigenetic reprogramming therapy using three transcription factors (OSK) to reset cellular aging patterns.
• Phase 1 trial evaluates safety and tolerability in optic neuropathies with visual function as an additional endpoint.
• Targets glaucoma and non-arteritic anterior ischemic optic neuropathy, both vision-threatening conditions.